c-erbB-2 expression is predictive for lymphatic spread of clinical gastric carcinoma. 1997

H Orita, and Y Maehara, and Y Emi, and Y Kakeji, and H Baba, and D Korenaga, and K Sugimachi
Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

OBJECTIVE In patients with gastric carcinoma, the prognostic significance of c-erbB-2 oncogene expression was elucidated, but its role in the aggressive behavior of tumors is not clear. METHODS We asked whether or not cerbB-2 gene expression may have predictability with regard to the metastatic potential in 160 patients with gastric carcinoma using a immunohistochemical staining and a multivariate analysis. RESULTS c-erbB-2 immunoreactivity was observed in 11% (17/160) of tumors. Patients with c-erbB-2 product positive tumors had a significant shorter prognosis (p < 0.05), and were characterized by a high incidence of peritoneal dissemination (41%), liver metastasis (18%) and lymph node involvement (94%). In the multivariate logistic analysis revealed that c-erbB-2 expression was a significant risk factor related to lymph node involvement (p < 0.01). CONCLUSIONS Our multivariate analysis revealed that c-erbB-2 expression is linked to the metastatic potential in patients with gastric carcinoma.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D013274 Stomach Neoplasms Tumors or cancer of the STOMACH. Cancer of Stomach,Gastric Cancer,Gastric Neoplasms,Stomach Cancer,Cancer of the Stomach,Gastric Cancer, Familial Diffuse,Neoplasms, Gastric,Neoplasms, Stomach,Cancer, Gastric,Cancer, Stomach,Cancers, Gastric,Cancers, Stomach,Gastric Cancers,Gastric Neoplasm,Neoplasm, Gastric,Neoplasm, Stomach,Stomach Cancers,Stomach Neoplasm
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival

Related Publications

H Orita, and Y Maehara, and Y Emi, and Y Kakeji, and H Baba, and D Korenaga, and K Sugimachi
December 2005, Digestive diseases and sciences,
H Orita, and Y Maehara, and Y Emi, and Y Kakeji, and H Baba, and D Korenaga, and K Sugimachi
January 2002, Pathology oncology research : POR,
H Orita, and Y Maehara, and Y Emi, and Y Kakeji, and H Baba, and D Korenaga, and K Sugimachi
May 1992, Journal of clinical pathology,
H Orita, and Y Maehara, and Y Emi, and Y Kakeji, and H Baba, and D Korenaga, and K Sugimachi
January 2019, Open life sciences,
H Orita, and Y Maehara, and Y Emi, and Y Kakeji, and H Baba, and D Korenaga, and K Sugimachi
January 1993, International surgery,
H Orita, and Y Maehara, and Y Emi, and Y Kakeji, and H Baba, and D Korenaga, and K Sugimachi
April 1992, Journal of surgical oncology,
H Orita, and Y Maehara, and Y Emi, and Y Kakeji, and H Baba, and D Korenaga, and K Sugimachi
January 2010, World journal of gastroenterology,
H Orita, and Y Maehara, and Y Emi, and Y Kakeji, and H Baba, and D Korenaga, and K Sugimachi
January 2001, The International journal of biological markers,
H Orita, and Y Maehara, and Y Emi, and Y Kakeji, and H Baba, and D Korenaga, and K Sugimachi
June 1997, World journal of gastroenterology,
Copied contents to your clipboard!